New analyses from the landmark PROactive study examined the effects of Actos on the risk of stroke and other cardiovascular outcomes in high-risk patients with type 2 diabetes, with and without prior stroke. Pre-specified study endpoints included all-stroke and cardiovascular disease death, myocardial infarction (MI) or stroke.
According to the results, there were statistically significant benefits of Actos in patients who had suffered a prior stroke. The incidence of recurrent stroke was reduced by 47% and the combined risk of death, MI or stroke was reduced by 28%.
There was no effect of Actos on subsequent strokes in patients who had never experienced a stroke.
“These results are very encouraging news for people with type 2 diabetes because they demonstrated that Actos reduced the incidence of strokes in patients who had already experienced a stroke from 10.2% down to 5.6 %, translating to a risk reduction of almost 50%,” said Robert Wilcox, professor in the department of cardiovascular medicine at University Hospital, Nottingham, UK.